Riverbridge Partners LLC Sells 45,878 Shares of Repligen Co. (NASDAQ:RGEN)

Riverbridge Partners LLC trimmed its holdings in Repligen Co. (NASDAQ:RGEN) by 9.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 455,098 shares of the biotechnology company’s stock after selling 45,878 shares during the quarter. Riverbridge Partners LLC’s holdings in Repligen were worth $65,507,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Ballentine Partners LLC increased its stake in Repligen by 4.0% in the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 72 shares during the period. Toronto Dominion Bank increased its stake in shares of Repligen by 1.5% in the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after buying an additional 75 shares during the period. MML Investors Services LLC increased its stake in shares of Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after buying an additional 89 shares during the period. GAMMA Investing LLC raised its holdings in Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 90 shares during the last quarter. Finally, UMB Bank n.a. boosted its position in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on RGEN shares. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $185.20.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $166.84 on Thursday. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a 50-day moving average of $149.17 and a 200 day moving average of $145.43.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter last year, the firm earned $0.23 earnings per share. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. Research analysts anticipate that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.